HRHindun Wilda Risni

Hindun Wilda Risni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hindun Wilda Risni has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis

    by Ilil Maidatuz Zulfa, Hindun Wilda Risni, Ruth Brauer, Cate Whittlesea, Li Wei

    Calcium channel blockers (CCBs) and statins are commonly combined to prevent cardiovascular diseases (CVDs). However, their concomitant use may lead to drug-drug interactions (DDIs) and increased adverse effects (AEs). This systematic review and meta-analysis aimed to evaluate the evidence of adverse effects (AEs) associated with the calcium channel blockers (CCBs) and statins concomitant use. We searched MEDLINE, Embase, Web of Science, and CENTRAL from database inception to 4 April 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies reporting AEs of CCB-statin combinations compared with CCB or statin treatment in adults. Outcomes assessed included CCBs- and statins-associated AEs, treatment discontinuation, hospitalization, and all-cause mortality. Meta-analyses of similar outcomes were performed to estimate pooled Odds Ratios (OR) with 95% confidence intervals (CI). Of 9,737 articles screened, 20 studies (n = 1,053,198) were included. Peripheral edema, myalgia, and discontinuation were most reported in 11, 7, and 9 studies, respectively. Meta-analyses demonstrated no significant differences in the risk of peripheral edema (OR 1.03, 95% CI 0.14-1.48), myalgia (OR 1.33, 95% CI 0.63-2.79), or discontinuation (OR 0.78, 95% CI 0.50-1.23 for CCB-statin vs. CCB; OR 0.97, 95% CI 0.68-1.38 for CCB-statin vs. statin). However, evidence of other AEs was inconsistent and limited. CCB-statin combination appears generally safe in a short-term use (3 to 6 months). Further research is warranted to clarify the long-term risk of AEs.


  • Open Access

    Trends in Government‐Subsidised Menopausal Hormone Therapy Dispensing in Australia Between 2014 and 2023

    by Hindun Wilda Risni, Li Wei, Martha Hickey, Luke Grzeskowiak, Jenni Ilomäki, Ruth Brauer

    Menopausal hormone therapy (MHT) is a mainstay treatment for menopausal symptoms. While international studies report rising MHT use, trends in Australia remain unclear. Using a 10% random sample of Pharmaceutical Benefits Scheme (PBS) data from 2014 to 2023, we analysed the prevalence of MHT dispensing among women aged 45–64. Overall prevalence of MHT dispensing remained stable (relative annual change: 0.42%, 95% CI −0.50 to 1.35). Use of transdermal and intrauterine device (IUD) MHT increased (5.89%, 95% CI 3.88–7.91 and 10.22%, 95% CI 9.48–10.95, respectively), and vaginal MHT decreased (−1.47%, 95% CI −2.30 to −0.63), while oral MHT appeared stable (0.66%, 95% CI −0.04 to 1.36). This study offers a clearer understanding of how MHT use in Australia has changed over the last decade.


  • Open Access

    The effect of cognitive decline on the medication adherence in patients with type II diabetes mellitus

    by Indana Ayu Soraya, Rani Sauriasari, Pukovisa Prawirohardjo, Hindun Wilda Risni

    Background: Type II Diabetes Mellitus (T2DM) is a risk factor for decreased cognitive function that is rarely recognised by patients, apart from age and other factors. Objective: This study aims to assess the effect of decreased cognitive function on medication adherence in T2DM patients. Method: This study used a cross-sectional design conducted at the Pasar Minggu Community Health Center, Jakarta, Indonesia. Cognitive function was assessed using the validated Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina) questionnaire. Results: One hundred twenty-seven T2DM patients (75.6% female) with a mean age of 58.69 years were recruited. The proportion of T2DM patients with decreased cognitive function was quite high, namely 61%. The proportion of non-adherent patients in the group with decreased cognitive function (70.6%) was greater than in the normal group (29.4%). Decreased cognitive function significantly affected non-adherence in taking medication with aOR 3.744 (95% CI 1.485–9.442), p = 0.005, after controlling for age, education level, HbA1c value, and comorbid dyslipidemia. Conclusion: Patients with decreased cognitive function are 3.7 times more likely to be non-compliant with medication, regardless of age, education level, HbA1c value, and dyslipidemia. Special management is needed for T2DM patients with decreased cognitive function, such as caregiver assistance, education by pharmacists, and simpler drug regimes.


  • Open Access

    Analysis of drug-related problems in ischemic stroke in-patients in one Indonesian district hospital

    by Retnosari Andrajati, Larasati Arrum Kusumawardani, Isti Nurul Afifah, Hindun Wilda Risni

    Background: Ischemic stroke is one of the leading causes of death in Indonesia. Appropriate management, including the identification of drug-related problems (DRPs), is needed to prevent disability and death. Objective: This study aimed to analyse DRPs as defined by the Pharmaceutical Care Network Europe (PCNE). Method: This was a cross-sectional research using the medical records of in-patients with ischemic stroke aged >18 years. Result: Out of the 115 patients examined, 51.3% were male, and the mean age was 57.85 + 10.539 years. Exactly 204 cases of DRPs and 175 causes appeared in 101 patients. A total of 58 patients experienced one-to-two problems, and 43 patients experienced more than two problems. The problems domain consists of therapeutic effectiveness (P1, 133(65.2%)), adverse effects (P2, 67(32, 84%)), and medical expenses (P3, 4(1, 96%)). The DRPs mostly involved antihypertension and antiplatelet. The most common cause was a new indication for treatment (C1.9, 51(29.14%)) and drug interactions (C8.1, 48(27.43%)). Multivariate analysis of patient characteristics showed that patients taking more than eight medications were more likely to experience more than two DRPs than those on one-to-four medications (OR 5.593; 95%, CI 1.015-30.812). Conclusion: Most patients experienced one-to-two DRPs with the highest being a potentially suboptimal treatment. Clinical pharmacists are expected to monitor therapy, especially in polypharmacy patients.


  • Open Access

    Evaluation of the Use of Antimicrobial Therapy for Treating Diabetic Foot Infections in an Indonesia Referral Hospital: A Retrospective Cohort Study

    by Memy Aviatin, Rani Sauriasari, Em Yunir, Hindun Wilda Risni

    Aviatin M, et al. Infect Chemother. 2023 Mar;55(1):80-89. https://doi.org/10.3947/ic.2022.0084


  • Open Access

    A Systematic Review of Randomized Controlled Trials of Antibiotic Use in Diabetic Foot Ulcer Infections: Focus on Clinical Cure

    by Vincent Pratama, Hindun Wilda Risni, Em Yunir, Rani Sauriasari

    Pratama V, et al. Infect Chemother. 2022 Mar;54(1):125-139. https://doi.org/10.3947/ic.2021.0144